A Study of Risvutatug Rezetecan in Combination With Atezolizumab in Participants With Extensive Stage Small Cell Lung Cancer (EMBOLD-SCLC-303)
A Phase 3 Randomized Open-Label Study to Evaluate the Safety and Efficacy of Risvutatug Rezetecan in Combination With Atezolizumab in Participants With Newly Diagnosed Extensive Stage Small Cell Lung Cancer
Extensive-stage small cell lung cancer (ES-SCLC) is an aggressive type of lung cancer. Current treatment options are limited, and response to treatment may not last long. Outcomes are especially poor when the cancer has spread to the brain. This study tests whether a new treatment: risvutatug rezetecan (Ris-Rez) with atezolizumab works better than standard of care treatment. Ris-Rez is designed to deliver cancer-killing medicine directly to cancer cells. Atezolizumab helps the immune system attack cancer cells. Researchers will see if this combination helps people live longer and keeps the cancer from getting worse.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Faza
Faza
- Faza 3
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: US GSK Clinical Trials Call Center
- Numer telefonu: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
Kopia zapasowa kontaktu do badania
- Nazwa: EU GSK Clinical Trials Call Center
- Numer telefonu: +44 (0) 20 89904466
- E-mail: GSKClinicalSupportHD@gsk.com
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Is at least 18 years of age or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the informed consent form (ICF).
- Has histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC) at initial diagnosis and at trial entry and has received no prior systemic therapies for SCLC, with 1 exception where participants who have received one cycle of etoposide and carboplatin with or without atezolizumab are eligible
- Is capable of giving signed informed consent including compliance with the requirements and restrictions listed in the ICF and protocol.
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Has adequate organ function.
Exclusion Criteria:
- Has symptomatic central nervous system (CNS) metastases, CNS metastases with hemorrhagic features, or leptomeningeal disease.
- Has known allergy or hypersensitivity to study intervention components or excipients.
- Has any evidence of current interstitial lung disease or non-infectious pneumonitis or a prior history of interstitial lung disease (ILD) or non-infectious pneumonitis requiring high dose steroids or suspected ILD/non-infectious pneumonitis that cannot be ruled out by imaging.
- Has moderate to severe pulmonary disease or current clinically significant pulmonary compromise that, in the investigator's judgment, could jeopardize safety or study conduct.
- Has clinically significant bleeding symptoms, bleeding tumors, or significant bleeding tendency within 1 month prior to first dose.
- Known active infectious diseases requiring systemic treatment or known human immunodeficiency virus (HIV).
- Has received any prior systemic anticancer treatment for the disease under study.
- Has received any prior therapy with a Topoisomerase-1 (TOP1i), including antibody-drug conjugates that are effectively loaded as TOP1i, or treatment targeting B7-H3.
- Has severe, uncontrolled, or active cardiovascular disorders.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: Ris-Rez + atezolizumab
|
Ris-Rez will be administered. Atezolizumab will be administered. |
|
Aktywny komparator: Etoposide, carboplatin, atezolizumab ± lurbinectedin
Participants will receive etoposide, carboplatin, atezolizumab with or without lurbinectedin. |
Carboplatin will be administered. Atezolizumab will be administered. Etoposide will be administered. Lurbinectedin will be administered. |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Overall survival (OS)
Ramy czasowe: Up to 50 months
|
OS is defined as the time from the date of randomization to the date of death due to any cause. |
Up to 50 months
|
|
Progression-free survival (PFS) by Blinded independent central review (BICR) assessment
Ramy czasowe: Up to 50 months
|
PFS is defined as the time from the date of randomization to the date of first documented objective tumor progression per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by BICR assessment or death from any cause, whichever occurs first. |
Up to 50 months
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Time to confirmed deterioration of disease-related symptoms and physical functioning
Ramy czasowe: Up to 63 months
|
Time from the date of randomization to the first confirmed clinically meaningful deterioration in disease related symptoms and physical functioning using validated questionnaires will be measured. |
Up to 63 months
|
|
Brain PFS
Ramy czasowe: Up to 63 months
|
Brain PFS is defined as the time from the date of randomization to the date of first documented brain disease progression (PD) per modified Response assessment in neuro-oncology brain metastases (RANO-BM) by BICR assessment or death from any cause, whichever occurs first in participants with a presence of brain metastases at baseline. |
Up to 63 months
|
|
PFS by Investigator Assessment
Ramy czasowe: Up to 63 months
|
PFS is defined as the time from the date of randomization to the date of first documented PD per RECIST 1.1 by investigator assessment or death from any cause, whichever occurs first. |
Up to 63 months
|
|
Objective response rate (ORR)
Ramy czasowe: Up to 63 months
|
ORR is defined as the percentage of participants with best overall confirmed response of either complete response (CR) or partial response (PR) per RECIST 1.1 by RECIST-BICR assessment. |
Up to 63 months
|
|
Duration of response (DOR)
Ramy czasowe: Up to 63 months
|
DOR is defined as the time from the date of first documented objective response (CR or PR) that is subsequently confirmed per RECIST 1.1 by RECIST-BICR assessment to the date of first documented PD per RECIST 1.1 by BICR assessment or death due to any cause, whichever occurs first. |
Up to 63 months
|
|
ORR for participants not receiving bridging cycle
Ramy czasowe: Up to 63 months
|
ORR is defined as the percentage of participants with best overall confirmed response of either CR or PR per RECIST 1.1 by RECIST-BICR assessment |
Up to 63 months
|
|
DOR for participants not receiving bridging cycle
Ramy czasowe: Up to 63 months
|
DOR is defined as the time from the date of first documented objective response (CR or PR) that is subsequently confirmed per RECIST 1.1 by RECIST-BICR assessment to the date of first documented PD per RECIST 1.1 by BICR assessment or death due to any cause, whichever occurs first. |
Up to 63 months
|
|
Participant reported experience on study treatment
Ramy czasowe: Up to 63 months
|
Number of participants who reported their experience with study treatment using validated questionnaires will be measured. |
Up to 63 months
|
|
Time to worsening of participants overall quality of life
Ramy czasowe: Up to 63 months
|
Time from the date of randomization to the first confirmed clinically meaningful deterioration in overall quality of life using validated questionnaires will be measured. |
Up to 63 months
|
|
Number of participants with adverse events (AEs), serious adverse events (SAEs), adverse events of special interest (AESIs) by severity
Ramy czasowe: Up to 63 months
|
Up to 63 months
|
|
|
Number of participants with AEs leading to dose modifications or study intervention discontinuation
Ramy czasowe: Up to 63 months
|
Up to 63 months
|
|
|
Number of participants with changes in hematology parameters
Ramy czasowe: Up to 63 months
|
Up to 63 months
|
|
|
Observed pharmacokinetic concentration of Ris-Rez
Ramy czasowe: Up to 63 months
|
Up to 63 months
|
|
|
Number of participants with Antidrug antibody (ADA) and Neutralizing Antibody (NAb) against Ris-Rez
Ramy czasowe: Up to 63 months
|
Up to 63 months
|
|
|
Titres of ADA against Ris-Rez
Ramy czasowe: Up to 63 months
|
Up to 63 months
|
Współpracownicy i badacze
Sponsor
Sponsor
Śledczy
Śledczy
- Dyrektor Studium: GSK Clinical Trials, GlaxoSmithKline
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Nowotwory według lokalizacji
- Nowotwory
- Choroby Układu Oddechowego
- Choroby płuc
- Nowotwory Układu Oddechowego
- Nowotwory klatki piersiowej
- Rak, Bronchogenny
- Nowotwory oskrzeli
- Nowotwory płuc
- Rak Drobnokomórkowy Płuc
- Organiczne chemikalia
- Węglowodory
- Węglowodory, cykliczne
- Węglowodany
- Podofilotoksyna
- Tetrahydronafthalenes
- Naftaleny
- Policykliczne aromatyczne węglowodory
- Węglowodory, aromatyczne
- Związki policykliczne
- Glukozydy
- Glikozydy
- Kompleksy koordynacyjne
- Etopozyd
- Karboplatyna
- PM 01183
- Atezolizumab
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- 300599
- 2026-527806-19 (Inny identyfikator: EU CT Number)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf
Ramy czasowe udostępniania IPD
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
Kryteria dostępu do udostępniania IPD
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
Typ informacji pomocniczych dotyczących udostępniania IPD
- PROTOKÓŁ BADANIA
- SOK ROŚLINNY
- ICF
- CSR
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .